肠炎康联合美沙拉嗪治疗溃疡性结肠炎  

Treatment Effect of Ulcerative Colitis Coalescent with Changyankang and Metalizing

作　　者：邹琳[1] 苑军伟[1] 白蔷薇[1] 金吉[1] 毛庆琳[1] 董宇翔[1] 

机构地区：[1]吉林大学第一医院,长春130021

出　　处：《中国实验方剂学杂志》2013年第9期323-325,共3页Chinese Journal of Experimental Traditional Medical Formulae

摘　　要：目的:比较肠炎康联合美沙拉嗪与美沙拉嗪治疗溃疡性结肠炎的疗效,为临床治疗溃疡性结肠炎提供合理用药的建议。方法:将吉林大学第一医院2010年6月-2011年5月门诊收治的溃疡性结肠炎患者90例,随机分为治疗组45例和对照组45例,分别接受肠炎康联合美沙拉嗪与美沙拉嗪的治疗方法,用药后对两组的治疗有效率、结肠镜下形态变化及C-反应蛋白及血沉等进行比较,评价其疗效及安全性。结果:两组治疗后的有效率、结肠镜下形态变化比较均具有统计学意义(P<0.05)。结论:肠炎康联合美沙拉嗪的疗效优于美沙拉嗪,值得临床推广应用。Objective：Compare the proposed traditional prescription joint metalizing and mesalazine treatment the curative effect of ulcerative colitis,provide rational drug use advice for clinical treatment of ulcerative colitis.Method： Ninty cases of ulcerative colitis patients in our hospital from June 2010 to May 2011,randomly divided into treatment group（45 cases） and control group（45 cases）,were given the proposed traditional prescription joint mesalazine and mesalazine treatment respectively.After that,compare with two groups of treatment effective rate,under colonoscopy form change,C-reactive protein（CRP）,ergthrocyte sedimentration rate（ESR） etc,evaluate its effectiveness and safety.Result： The treatment effective rate and under colonoscopy form change of the two groups after treatment are all have statistical significance（P＆lt;0.05）.Conclusion： The curative effect of the proposed traditional prescription joint mesalazine is better than that of mesalazine.It is worthy of clinical application.

关 键 词：肠炎康 自拟中药方 美沙拉嗪 溃疡性结肠炎 结肠镜 C-反应蛋白 血沉 

分 类 号：R287[医药卫生—中药学]